Literature DB >> 12027777

Strategy for the management of vasovagal syncope.

Daniel M Bloomfield1.   

Abstract

The disorders of autonomic control associated with orthostatic intolerance are a diverse group of syndromes that can result in syncope and near-syncope. A basic understanding of the pathophysiology of these disorders is essential to diagnosis and proper treatment. It is especially important to recognise the difference between the effect of prolonged upright posture on a failing autonomic nervous system (a hyposensitive or dysautonomic response) and the vasovagal response (which may be a hypersensitive response). Vasovagal syncope is the most common abnormal response to upright posture and occurs in all age groups. The advent of tilt table testing has helped define a population with an objective finding during provocative testing that has enabled researchers to study the mechanism of vasovagal syncope and to evaluate the efficacy of treatments. In most patients, vasovagal syncope occurs infrequently and only under exceptional circumstances and treatment is not needed. Treatment may be indicated in patients with recurrent syncope or with syncope that has been associated with physical injury or potential occupational hazard. Based on study data, patients with vasovagal syncope can now be risk stratified into a high-risk group likely to have recurrent syncope and a low-risk group. Many patients with vasovagal syncope can be effectively treated with education, reassurance and a simple increase in dietary salt and fluid intake. In others, treatment involves removal or avoidance of agents that predispose to hypotension or dehydration. However, when these measures fail to prevent the recurrence of symptoms, pharmacological therapy is usually recommended. Although many pharmacological agents have been proposed and/or demonstrated to be effective based on nonrandomised clinical trials, there is a remarkable absence of data from large prospective clinical trials. Data from randomised placebo-controlled studies support the efficacy of beta-blockers, midodrine, serotonin reuptake inhibitors and ACE inhibitors. There is also considerable clinical experience and a consensus suggesting that fludrocortisone is effective. Encouraging new data suggest that a programme involving tilt training can effectively prevent vasovagal syncope. For patients with recurrent vasovagal syncope that is refractory to these treatments, implantation of a permanent pacemaker with specialised sensing/pacing algorithms appears to be effective. A number of larger clinical trials are underway which should help further define the efficacy of a number of different treatments for vasovagal syncope.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12027777     DOI: 10.2165/00002512-200219030-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  92 in total

Review 1.  Putting it together: a new treatment algorithm for vasovagal syncope and related disorders.

Authors:  D M Bloomfield; R Sheldon; B P Grubb; H Calkins; R Sutton
Journal:  Am J Cardiol       Date:  1999-10-21       Impact factor: 2.778

2.  Recommendations for pacemaker prescription for symptomatic bradycardia. Report of a working party of the British Pacing and Electrophysiology Group.

Authors: 
Journal:  Br Heart J       Date:  1991-08

3.  Effects of transdermal scopolamine on heart rate variability in normal subjects.

Authors:  T Vybiral; R J Bryg; M E Maddens; S S Bhasin; S Cronin; W E Boden; M H Lehmann
Journal:  Am J Cardiol       Date:  1990-03-01       Impact factor: 2.778

4.  The economics of treating vasovagal syncope.

Authors:  R Sutton; M E Petersen
Journal:  Pacing Clin Electrophysiol       Date:  1997-03       Impact factor: 1.976

5.  The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing.

Authors:  B P Grubb; D J Kosinski; K Boehm; K Kip
Journal:  Pacing Clin Electrophysiol       Date:  1997-09       Impact factor: 1.976

6.  Increased activity in left ventricular receptors during hemorrhage or occlusion of caval veins in the cat. A possible cause of the vaso-vagal reaction.

Authors:  B Oberg; P Thorén
Journal:  Acta Physiol Scand       Date:  1972-06

7.  Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine.

Authors:  M Biffi; G Boriani; P Sabbatani; G Bronzetti; L Frabetti; R Zannoli; A Branzi; B Magnani
Journal:  Heart       Date:  1997-03       Impact factor: 5.994

8.  Effect of beta blockers on the time to first syncope recurrence in patients after a positive isoproterenol tilt table test.

Authors:  R Sheldon; S Rose; P Flanagan; M L Koshman; S Killam
Journal:  Am J Cardiol       Date:  1996-09-01       Impact factor: 2.778

9.  Efficacy of different treatment strategies for neurocardiogenic syncope.

Authors:  A Natale; J Sra; A Dhala; A Wase; M Jazayeri; S Deshpande; Z Blanck; M Akhtar
Journal:  Pacing Clin Electrophysiol       Date:  1995-04       Impact factor: 1.976

10.  Fluoxetine hydrochloride for the treatment of severe refractory orthostatic hypotension.

Authors:  B P Grubb; D Samoil; D Kosinski; D Wolfe; M Lorton; E Madu
Journal:  Am J Med       Date:  1994-10       Impact factor: 4.965

View more
  1 in total

1.  Baseline heart rate variability in children and adolescents with vasovagal syncope.

Authors:  Sun Hee Shim; Sun-Young Park; Se Na Moon; Jin Hee Oh; Jae Young Lee; Hyun Hee Kim; Ji Whan Han; Soon Ju Lee
Journal:  Korean J Pediatr       Date:  2014-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.